Annual Report

The report highlights GSK’s 2009 pipeline progress, including 12 product approvals and 11 new filings. Its global lymphatic-filariasis effort donated 425 million albendazole treatments to 28 countries. Environmental performance included a 5% reduction in emissions and a 6% reduction in energy consumption per unit of sales.